Physician profile
Erick M Brown
NPI 1689834335
$7,732.94
in general payments reported to CMS, 2019-2025
33 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,916 · 2020: $478 · 2021: $329 · 2022: $245 · 2023: $1,543 · 2024: $1,525 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,765.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,139.92 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,025.69 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $496.85 | 2019-2025 | Spravato |
| Lundbeck LLC | $490.30 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $435.49 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $433.66 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $423.05 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $395.62 | 2019-2025 | Trintellix |
| Corium, LLC | $350.37 | 2022-2024 | Azstarys |
| Allergan, INC. | $328.89 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $311.86 | 2019-2025 | Fanapt, Hetlioz |
| Avanir Pharmaceuticals, INC. | $224.76 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $192.51 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Neos Therapeutics, Lp | $187.24 | 2019-2023 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $180.19 | 2022-2025 | Qelbree, Qelbree |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $154.72 | 2019-2024 | |
| Tris Pharma INC | $132.88 | 2019-2025 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $125.18 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $83.26 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $73.75 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $73.50 | 2022-2025 | Nuplazid |
| Merck Sharp & Dohme LLC | $70.66 | 2020-2023 | Belsomra |
| Shire North American Group INC | $64.86 | 2019 | |
| Alkermes, INC. | $64.20 | 2023-2024 | Aristada, Lybalvi |
| Biogen, INC. | $57.90 | 2021-2024 | |
| Arbor Pharmaceuticals, INC. | $49.08 | 2019-2020 | |
| Almatica Pharma LLC | $47.82 | 2024-2025 | Loreev Xr |
| Bausch Health US, LLC | $41.31 | 2019-2023 | Wellbutrin, Aplenzin |
| Alfasigma USA, INC. | $20.49 | 2020 | |
| Eisai INC. | $15.83 | 2020 | |
| Amgen INC. | $15.82 | 2019 | |
| Adlon Therapeutics L.P. | $13.72 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.